Adaptive Phage Therapeutics, Inc.
708 Quince Orchard Blvd.
About Adaptive Phage Therapeutics, Inc.
Adaptive Phage Therapeutics (APT) is a clinical-stage company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria.
APT’s approach arms us with the unique capability of adapting to the emergence of future antibiotic-resistant superbugs. Our PhageBank’s precision targeted, genomically screened, and highly purified phage collection is dynamically expanding in response to the emergence of new strains of bacterial superbugs.
47 articles about Adaptive Phage Therapeutics, Inc.
Adaptive Phage Therapeutics Closes on $12 Million Investment in $30 Million Series B1 to Fight Antibiotic Resistant Infections
Adaptive Phage Therapeutics announced that it has received a $12 million upfront investment from funds managed by Deerfield Management and the AMR Action Fund as part of a new $24 million total investment in a Series B1 round that is targeting $30 million in aggregate.
Adaptive Phage Therapeutics Enters Collaboration and License Agreement with Hebrew University of Jerusalem and Hadassah Medical Center
Adaptive Phage Therapeutics is pleased to announce a collaboration and license agreement with the Israeli Phage Therapy Center (IPTC) of the Hebrew University of Jerusalem and Hadassah Medical Center.
Adaptive Phage Therapeutics Announces First Patient Dosed in the PHAGE Clinical Trial Evaluating Phage Therapy in Cystic Fibrosis-related Respiratory Infection
Adaptive Phage Therapeutics, Inc., today announced the first patient has been dosed in the PHAGE clinical trial, evaluating bacteriophage therapy in adults with cystic fibrosis (CF) who carry Pseudomonas aeruginosa ( P. aeruginosa ) in their lungs.
New Movers & Shakers took over the roles of chief executive officer, chief financial officer, chief medical officer and more at companies including Scenic Biotech, Biofrontera and X4 Pharmaceuticals.
Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company advancing a phage bank, the world’s largest therapeutic phage initiative for treatment of bacterial infectious diseases, today announced the appointment of Edward Fang, M.D. as Chief Medical Officer.
Adaptive Phage Therapeutics Awarded Additional $5 Million from U.S. Defense Health Agency to Support Diabetic Foot Osteomyelitis Clinical Trial
Adaptive Phage Therapeutics, Inc. announced that the Defense Health Agency has awarded an additional $5 million to support clinical development of APT’s adaptive bacteriophage therapy in treatment of diabetic foot osteomyelitis.
Adaptive Phage Therapeutics Announces "The AMR RAPID™ Challenge" for the Infectious Disease Research Community: Find a Bacteria Resistant to APT’s Investigational Phage Bank
Adaptive Phage Therapeutics, Inc. announced “The AMR RAPID™ Challenge” at the World AMR Congress.
Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.
Adaptive Phage Therapeutics Announces First Patient Dosed in the DANCE Trial, a Phase 1/2 Study Evaluating APT Phage Bank in Diabetic Foot Osteomyelitis
Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the first patient has been dosed in its DFO Adaptive Novel Care Evaluation (DANCE™) trial,
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
Adaptive Phage Therapeutics, Inc. today announced the appointment of Rob Casper as Vice President of Clinical Operations.
4/6/2022The AMR Action Fund financed two of this week’s money moves. Other moves ranged from medical devices to wearable sensor data companies. For that and more, continue reading.
Adaptive Phage Therapeutics, Inc., a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, announced that the AMR Action Fund has joined an existing $41 million Series B round as a co-investor.
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
Adaptive Phage Therapeutics Announces Strategic Agreement with ARLG to Support Phase 1b/2 Cystic Fibrosis Study
Adaptive Phage Therapeutics, Inc. (APT), today announced that it has entered into an agreement with the Antibacterial Resistance Leadership Group (ARLG) to support a multi-center Phase 1b/2, randomized, double-blind, placebo-controlled trial assessing the safety and microbiological activity of a single dose of bacteriophage therapy in cystic fibrosis subjects colonized with Pseudomonas aeruginosa.
Adaptive Phage Therapeutics Awarded Additional $8 Million from U.S. Department of Defense for Clinical Advancement of Phage to Address Unmet Needs in Infectious Diseases
Adaptive Phage Therapeutics, Inc. today announced that the Department of Defense (DoD) has awarded the company an additional $8 million for the continued development of bacteriophage therapies (PhageBankTM) for the treatment of infectious diseases.
As the 10th annual IDWeek (Infectious Disease Week) Conference begins, treatments aimed at COVID-19 will certainly dominate the program.
Adaptive Phage Therapeutics, Inc. today announced that it has appointed Michele Wales, Ph.D., J.D., as Chief Legal Officer. Dr. Wales joins APT with extensive experience in litigation and intellectual property law, specifically within the life sciences industry.
9/17/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Adaptive Phage Therapeutics, Inc. today announced the appointment of Jesse L. Goodman, MD, MPH, to the company’s Board of Directors.